source
- RA Capital leads $175 million round for Oak Hill Bio to revive Roche’s Angelman syndrome drugRA Capital and other investors have committed $175 million to Oak Hill Bio, a new biotech aiming to revive a previously shelved experimental therapy for Angelman syndrome originally developed by Ro…
- Schrödinger launches AI agent Bunsen, CEO admits earlier AI skepticism was wrongSchrödinger announced the debut of its new AI agent, Bunsen, which is built on the company’s physics‑based software platform. The tool is intended to help biopharma researchers model molecular beha…